The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2022 | Advances in the science and treatment of MPNs
Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, gives a detailed overview of recent advances in the treatment of myeloproliferative neoplasms (MPNs), including ongoing clinical trials and novel agents. Dr Mesa first highlights novel therapies being developed for essential thrombocythemia (ET) and polycythemia vera (PV), including ropeginterferon, and ongoing trials in this area. Dr Mesa then discusses the promise of novel agents such as rusfertide, and further explains advances in the use of various JAK inhibtors for the the treatment of myelofibrosis, including fedratinib, pacritinib, and momelotinib. To conclude, Dr Mesa highlights the importance of novel combination therapies and their role in the future of MPN treatment. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
